<?xml version="1.0" encoding="UTF-8"?>
<p>Original studies investigating the effectiveness of medicinal cannabinoids in the treatment of PTSD diagnosed according to the DSM criteria were deemed eligible for inclusion, according to the PICO methodology. Literature considering specific symptoms of PTSD as treatment outcomes was also evaluated for the present review, with no language limits. Grey literature was included whenever sufficient information was provided. Articles presenting only an opinion or hypothesis without empirical investigation, reviews, letters to the editor, and commentaries were excluded. Case series were included if sufficient information was given. Studies reporting data on genetic and molecular aspects in animal models were not deemed eligible for the present review. As for studies with overlapping samples, more than one article was considered for inclusion if reporting on different aspects of the considered outcomes. </p>
